Prognostic role of neuroendocrine differentiation in prostate cancer, putting together the pieces of the puzzle
暂无分享,去创建一个
L. Dogliotti | F. Vignani | V. Bertaglia | M. Tucci | A. Berruti | M. Poggio | L. Russo | Mattia Tullio
[1] M. Papotti,et al. The prognostic role of immunohistochemical chromogranin a expression in prostate cancer patients is significantly modified by androgen‐deprivation therapy , 2010, The Prostate.
[2] P. Magni,et al. Regulation of prostate cancer cell proliferation by somatostatin receptor activation , 2010, Molecular and Cellular Endocrinology.
[3] G. Buchanan,et al. TGF-β signalling and immunity in prostate tumourigenesis , 2010, Expert opinion on therapeutic targets.
[4] A. Hussain,et al. The relationship of neuroendocrine carcinomas to anti‐tumor therapies in TRAMP mice , 2009, The Prostate.
[5] M. Papotti,et al. Why castration-resistant prostate cancer patients with neuroendocrine differentiation should be addressed to a cisplatin-based regimen. , 2009, Annals of oncology : official journal of the European Society for Medical Oncology.
[6] C. Schade-Brittinger,et al. Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[7] K. Williams,et al. Selective expression of CD44, a putative prostate cancer stem cell marker, in neuroendocrine tumor cells of human prostate cancer , 2009, The Prostate.
[8] Z. Kusic,et al. Continuous finasteride therapy for benign prostate hypertrophy upgrades both neuroendorcine differentiation and aggressive prostate cancer. , 2009, Anticancer research.
[9] J. Thrasher,et al. Effects of short-term finasteride on apoptotic factors and androgen receptors in prostate cancer cells. , 2009, The Journal of urology.
[10] F. Abbas,et al. Correlation of three immunohistochemically detected markers of neuroendocrine differentiation with clinical predictors of disease progression in prostate cancer , 2008, BMC urology.
[11] Han Liu,et al. Ionizing radiation induces prostate cancer neuroendocrine differentiation through interplay of CREB and ATF2: implications for disease progression. , 2008, Cancer research.
[12] A. Partin,et al. Long‐Term assessment of prostate cancer progression free survival: Evaluation of pathological parameters, nuclear shape and molecular biomarkers of pathogenesis , 2008, The Prostate.
[13] R. Matusik,et al. The nuclear factor-kappaB pathway controls the progression of prostate cancer to androgen-independent growth. , 2008, Cancer research.
[14] I. Thompson,et al. Finasteride Does Not Increase the Risk of High-Grade Prostate Cancer: A Bias-Adjusted Modeling Approach , 2008, Cancer Prevention Research.
[15] H. Schmid. Pasireotide (SOM230): Development, mechanism of action and potential applications , 2008, Molecular and Cellular Endocrinology.
[16] H. Ishikura,et al. Neuroendocrine differentiation in stage D2 prostate cancers , 2008, International journal of urology : official journal of the Japanese Urological Association.
[17] T. Ecke,et al. Ki67 staining index and neuroendocrine differentiation aggravate adverse prognostic parameters in prostate cancer and are characterized by negligible inter-observer variability , 2008, World Journal of Urology.
[18] Susan Halabi,et al. Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[19] Francesco Porpiglia,et al. Human ASH1 expression in prostate cancer with neuroendocrine differentiation , 2008, Modern Pathology.
[20] R. Autorino,et al. Neuroendocrine Immunophenotype as Predictor of Clinical Recurrence in 110 Patients with Prostate Cancer , 2007, International journal of immunopathology and pharmacology.
[21] M. Papotti,et al. Chromogranin A expression in patients with hormone naïve prostate cancer predicts the development of hormone refractory disease. , 2007, The Journal of urology.
[22] Ming-Fong Lin,et al. Neuroendocrine-like prostate cancer cells: neuroendocrine transdifferentiation of prostate adenocarcinoma cells. , 2007, Endocrine-related cancer.
[23] Toscano Vincenzo,et al. Chromogranin A and biochemical progression-free survival in prostate adenocarcinomas submitted to radical prostatectomy. , 2007, Endocrine-related cancer.
[24] H. Frierson,et al. Androgen-independent growth and tumorigenesis of prostate cancer cells are enhanced by the presence of PKA-differentiated neuroendocrine cells. , 2007, Cancer research.
[25] Kogenta Nakamura,et al. An immunohistochemical study of chromogranin A and human epidermal growth factor‐2 expression using initial prostate biopsy specimens from patients with bone metastatic prostate cancer , 2007, BJU international.
[26] Jiaoti Huang,et al. Phosphatidylinositol 3-Kinase-AKT-Mammalian Target of Rapamycin Pathway Is Essential for Neuroendocrine Differentiation of Prostate Cancer* , 2006, Journal of Biological Chemistry.
[27] M. Papotti,et al. The grey zone between pure (neuro)endocrine and non-(neuro)endocrine tumours: a comment on concepts and classification of mixed exocrine–endocrine neoplasms , 2006, Virchows Archiv.
[28] P. di Sant'Agnese,et al. Immunohistochemical characterization of neuroendocrine cells in prostate cancer , 2006, The Prostate.
[29] J. Pinski,et al. Genistein‐induced neuroendocrine differentiation of prostate cancer cells , 2006, The Prostate.
[30] G. Semenza,et al. Regulation of angiogenesis by hypoxia-inducible factor 1. , 2006, Critical reviews in oncology/hematology.
[31] S. Slovin. Neuroendocrine differentiation in prostate cancer: a sheep in wolf's clothing? , 2006, Nature Clinical Practice Urology.
[32] R. Grobholz,et al. Genetic analysis of neuroendocrine tumor cells in prostatic carcinoma , 2006, The Prostate.
[33] Y. Yatabe,et al. ASH1 gene is a specific therapeutic target for lung cancers with neuroendocrine features. , 2005, Cancer research.
[34] H. Scher,et al. Biology of progressive, castration-resistant prostate cancer: directed therapies targeting the androgen-receptor signaling axis. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[35] C. Supuran,et al. Skewing towards neuroendocrine phenotype in high grade or high stage androgen-responsive primary prostate cancer. , 2005, European urology.
[36] P. Kantoff,et al. Prognostic significance of plasma chromogranin a levels in patients with hormone-refractory prostate cancer treated in Cancer and Leukemia Group B 9480 study. , 2005, Urology.
[37] S. Groshen,et al. Prognostic significance of neuroendocrine expression in lymph node-positive prostate cancer. , 2005, Urology.
[38] L. Dogliotti,et al. Independent prognostic role of circulating chromogranin A in prostate cancer patients with hormone-refractory disease. , 2005, Endocrine-related cancer.
[39] P. Abrahamsson,et al. Neuroendocrine differentiation in prostate cancer: implications for new treatment modalities. , 2005, European urology.
[40] Masaru Miyazaki,et al. Aberrant expression of human achaete-scute homologue gene 1 in the gastrointestinal neuroendocrine carcinomas. , 2005, Clinical cancer research : an official journal of the American Association for Cancer Research.
[41] B. Conley,et al. Detection of Prostate Cancer and Predicting Progression , 2004, Clinical Cancer Research.
[42] H. Asamura,et al. hASH1 expression is closely correlated with endocrine phenotype and differentiation extent in pulmonary neuroendocrine tumors , 2004, Modern Pathology.
[43] C. Korch,et al. Molecular characterization of human prostate carcinoma cell lines , 2003, The Prostate.
[44] Michael M Lieber,et al. Journal Review , 2003, International Society of Hair Restoration Surgery.
[45] Hubert Vesselle,et al. Phenotypic heterogeneity of end-stage prostate carcinoma metastatic to bone. , 2003, Human pathology.
[46] S. Monti,et al. Variation in chromogranin A serum levels during intermittent versus continuous androgen deprivation therapy for prostate adenocarcinoma , 2003, The Prostate.
[47] J. Cheville,et al. Metastatic prostate carcinoma to bone , 2002, Cancer.
[48] D. Bostwick,et al. Neuroendocrine expression in node positive prostate cancer: correlation with systemic progression and patient survival. , 2002, The Journal of urology.
[49] E. Lander,et al. Gene expression correlates of clinical prostate cancer behavior. , 2002, Cancer cell.
[50] T. H. van der Kwast,et al. Different profiles of neuroendocrine cell differentiation evolve in the PC‐310 human prostate cancer model during long‐term androgen deprivation , 2002, The Prostate.
[51] S. Parsons,et al. Interleukin-6- and Cyclic AMP-Mediated Signaling Potentiates Neuroendocrine Differentiation of LNCaP Prostate Tumor Cells , 2001, Molecular and Cellular Biology.
[52] D. Bostwick,et al. Neuroendocrine cells in human prostate over‐express the anti‐apoptosis protein survivin , 2001, The Prostate.
[53] R. Taylor,et al. Multipathways for transdifferentiation of human prostate cancer cells into neuroendocrine-like phenotype. , 2001, Biochimica et biophysica acta.
[54] L. Dogliotti,et al. Effects of the somatostatin analog lanreotide on the circulating levels of chromogranin‐A, prostate‐specific antigen, and insulin‐like growth factor‐1 in advanced prostate cancer patients , 2001, The Prostate.
[55] S. Fosså,et al. Prognostic value of neuroendocrine serum markers and PSA in irradiated patients with pN0 localized prostate cancer , 2001, The Prostate.
[56] J. Hugosson,et al. Neuroendocrine differentiation is not prognostic of failure after radical prostatectomy but correlates with tumor volume. , 2000, Urology.
[57] K. Alitalo,et al. VEGF‐C and VEGF‐D expression in neuroendocrine cells and their receptor, VEGFR‐3, in fenestrated blood vessels in human tissues , 2000, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[58] R. Montironi,et al. Vascular endothelial growth factor expression and capillary architecture in high‐grade PIN and prostate cancer in untreated and androgen‐ablated patients , 2000, The Prostate.
[59] L. Dogliotti,et al. Circulating neuroendocrine markers in patients with prostate carcinoma , 2000, Cancer.
[60] E. Bissonette,et al. Activated 3′,5′-Cyclic AMP-dependent Protein Kinase Is Sufficient to Induce Neuroendocrine-like Differentiation of the LNCaP Prostate Tumor Cell Line* , 2000, The Journal of Biological Chemistry.
[61] J. Overgaard,et al. Association between immunohistochemical expression of vascular endothelial growth factor (VEGF), VEGF-expressing neuroendocrine-differentiated tumor cells, and outcome in prostate cancer patients subjected to watchful waiting. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.
[62] J. Hugosson,et al. Regressive changes and neuroendocrine differentiation in prostate cancer after neoadjuvant hormonal treatment , 2000, The Prostate.
[63] T. Chung,et al. STAT3 mediates IL‐6‐induced neuroendocrine differentiation in prostate cancer cells , 2000, The Prostate.
[64] S. Lakhani,et al. Acquisition of neuroendocrine characteristics by prostate tumor cells is reversible: implications for prostate cancer progression. , 1999, Cancer research.
[65] H. Moch,et al. Focal neuroendocrine differentiation lacks prognostic significance in prostate core needle biopsies. , 1998, The Journal of urology.
[66] H. Frierson,et al. Cathepsin D and chromogranin A as predictors of long term disease specific survival after radical prostatectomy for localized carcinoma of the prostate , 1997, Cancer.
[67] J. Laissue,et al. Distribution of somatostatin receptors in normal and neoplastic human tissues: recent advances and potential relevance. , 1997, The Yale journal of biology and medicine.
[68] J. Olson,et al. Expression of neurogenic basic helix-loop-helix genes in primitive neuroectodermal tumors. , 1997, Cancer research.
[69] L. McWilliam,et al. Neuroendocrine differentiation and prognosis in prostatic adenocarcinoma. , 1997, British journal of urology.
[70] T. H. van der Kwast,et al. The prognostic value of neuroendocrine differentiation in adenocarcinoma of the prostate in relation to progression of disease after endocrine therapy. , 1997, The Journal of urology.
[71] S. Baylin,et al. An achaete-scute homologue essential for neuroendocrine differentiation in the lung , 1997, Nature.
[72] A. Partin,et al. Neuroendocrine differentiation in prostate cancer: enhanced prediction of progression after radical prostatectomy. , 1996, Human pathology.
[73] O. Cussenot,et al. Plasma neuroendocrine markers in patients with benign prostatic hyperplasia and prostatic carcinoma. , 1996, The Journal of urology.
[74] H. Moch,et al. Ki67 LABELLING INDEX: AN INDEPENDENT PREDICTOR OF PROGRESSION IN PROSTATE CANCER TREATED BY RADICAL PROSTATECTOMY , 1996, The Journal of pathology.
[75] T. H. van der Kwast,et al. The prognostic influence of neuroendocrine cells in prostate cancer: Results of a long‐term follow‐up study with patients treated by radical prostatectomy , 1995, International journal of cancer.
[76] O. Sartor,et al. A phase I study of the somatostatin analogue somatuline in patients with metastatic hormone‐refractory prostate cancer , 1995, Cancer.
[77] D. Bostwick,et al. Neuroendocrine Differentiation in Prostatic Intraepithelial Neoplasia and Adenocarcinoma , 1994, The American journal of surgical pathology.
[78] C. Logothetis,et al. SMS 201-995 in the treatment of refractory prostatic carcinoma. , 1994, Anticancer research.
[79] S. Frković-Grazio,et al. Immunohistochemical staining and serotest markers during development of a sarcomatoid and small cell prostate tumor. , 1994, Anticancer research.
[80] R. Cohen,et al. BCL-2 proto-oncogene expression in prostate cancer and its relationship to the prostatic neuroendocrine cell. , 1994, Archives of pathology & laboratory medicine.
[81] David J. Anderson,et al. Mammalian achaete-scute homolog 1 is required for the early development of olfactory and autonomic neurons , 1993, Cell.
[82] R. Bianchi,et al. Direct inhibitory effect of somatostatin on the growth of the human prostatic cancer cell line LNCaP: possible mechanism of action. , 1993, The Journal of clinical endocrinology and metabolism.
[83] S. Baylin,et al. Identification of a human achaete-scute homolog highly expressed in neuroendocrine tumors. , 1993, Proceedings of the National Academy of Sciences of the United States of America.
[84] S. Nakada,et al. The androgen receptor status of neuroendocrine cells in human benign and malignant prostatic tissue. , 1993, Cancer Research.
[85] M. Campbell,et al. Expression of the protooncogene bcl-2 in the prostate and its association with emergence of androgen-independent prostate cancer. , 1992, Cancer research.
[86] P. Scardino,et al. Elevated plasma chromogranin-A concentrations in prostatic carcinoma. , 1991, The Journal of urology.
[87] A. Bogdén,et al. Response of human lung tumor xenografts to treatment with a somatostatin analogue (Somatuline). , 1990, Cancer research.
[88] L. Grimelius,et al. Peptide-hormone- and serotonin-immunoreactive cells in normal and hyperplastic prostate glands. , 1986, Pathology, research and practice.
[89] G. Mendelsohn,et al. The histogenesis of small cell carcinoma of the prostate an immunohistochemical study , 1984, Cancer.
[90] A. Pearse,et al. Embryology of the diffuse neuroendocrine system and its relationship to the common peptides. , 1979, Federation proceedings.
[91] Y. Oshika,et al. P-glycoprotein-mediated acquired multidrug resistance of human lung cancer cells in vivo. , 1996, British Journal of Cancer.
[92] R. Dmochowski,et al. Open Access Journal of Urology , 2010 .
[93] J. Pinski,et al. Gene profiling and pathway analysis of neuroendocrine transdifferentiated prostate cancer cells , 2009, The Prostate.
[94] A. Borowsky,et al. Aberrant activation of androgen receptor in a new neuropeptide-autocrine model of androgen-insensitive prostate cancer. , 2009, Cancer research.
[95] 志田 崇. Aberrant expression of human achaete-scute homologue gene 1 in the gastrointestinal neuroendocrine carcinomas , 2007 .
[96] M. Stridsberg,et al. Octreotide scintigraphy and Chromogranin A do not predict clinical response in patients with octreotide acetate-treated hormone-refractory prostate cancer , 2006, Prostate Cancer and Prostatic Diseases.
[97] M. Housset,et al. Phase I–II study of the somatostatin analogue lanreotide in hormone-refractory prostate cancer , 2004, Cancer Chemotherapy and Pharmacology.
[98] M. Ahel,et al. Acquired neuroendocrine-positivity during maximal androgen blockade in prostate cancer patients. , 2002, Anticancer research.
[99] S. Cappia,et al. Relationship between neuroendocrine features and prognostic parameters in human prostate adenocarcinoma. , 2001, Annals of oncology : official journal of the European Society for Medical Oncology.
[100] H. Bonkhoff. Neuroendocrine differentiation in human prostate cancer. Morphogenesis, proliferation and androgen receptor status. , 2001, Annals of oncology : official journal of the European Society for Medical Oncology.
[101] P. di Sant'Agnese,et al. Neuroendocrine differentiation in prostatic carcinoma: an update on recent developments. , 2001, Annals of oncology : official journal of the European Society for Medical Oncology.
[102] P. A. Sant'agnese,et al. Neuroendocrine differentiation in prostatic carcinoma: an update on recent developments. , 2001, Annals of oncology : official journal of the European Society for Medical Oncology.
[103] Taosheng Chen,et al. Elevation of cyclic adenosine 3',5'-monophosphate potentiates activation of mitogen-activated protein kinase by growth factors in LNCaP prostate cancer cells. , 1999, Cancer research.
[104] H. Bonkhoff. Neuroendocrine cells in benign and malignant prostate tissue: Morphogenesis, proliferation, and androgen receptor status , 1998, The Prostate. Supplement.
[105] S. Nilsson,et al. [111In-DTPA-D-Phe1]-octreotide scintigraphy in patients with hormone-refractory prostatic adenocarcinoma can predict therapy outcome with octreotide treatment: a pilot study. , 1998, Anticancer research.
[106] P. di Sant'Agnese,et al. Prognostic significance of neuroendocrine differentiation in clinically localized prostatic carcinoma , 1998, The Prostate. Supplement.
[107] G Dhom,et al. Relation of endocrine‐paracrine cells to cell proliferation in normal, hyperplastic, and neoplastic human prostate , 1991, The Prostate.